0M61.BE - Myomo Inc
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.4840 |
| Open | 0.4780 |
| Bid | 0.4720 x N/A |
| Ask | 0.5350 x N/A |
| Day's Range | 0.4660 - 0.5150 |
| 52 Week Range | 0.3420 - 2.2000 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Aug 01, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
ZacksHere's Why Myomo, Inc. (MYO) Is a Great 'Buy the Bottom' Stock Now
Myomo, Inc. (MYO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
ZacksMyomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 26.67% and 3.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksSupernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Beat Estimates
Supernus (SUPN) delivered earnings and revenue surprises of 141.67% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksOwens & Minor (OMI) Beats Q1 Earnings and Revenue Estimates
Owens & Minor (OMI) delivered earnings and revenue surprises of 155.56% and 4.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireMyomo to Report First Quarter Financial Results on May 10, 2023
BOSTON, May 03, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months ended March 31, 2023 on May 10, 2023.
Business WireMyomo Receives Technology License Fee Payment from China Joint Venture Company
BOSTON, April 10, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces receipt of the final portion of the initial license fee under the Technology License Agreement with its joint venture company in China, Jiangxi Myomo Medical Assistive Appliance Co. Ltd. (the "JV Company").
The Wall Street JournalSVB Collapse Spurs Finance Executives to Re-Evaluate Cash Strategies
Financial officers at companies with money held at Silicon Valley Bank are re-evaluating their cash-management strategies in the wake of the bank’s collapse, a reckoning that comes after many firms feared they also would go under without access to their funds.
Business WireMyomo Makes NYSE American Section 610(b) Public Announcement
BOSTON, March 15, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2022 filed on March 13, 2023 with the Securities and Exchange Commission, the audited financial statements for the year ended December 31, 2022 included in t
Insider MonkeyMyomo, Inc. (AMEX:MYO) Q4 2022 Earnings Call Transcript
Myomo, Inc. (AMEX:MYO) Q4 2022 Earnings Call Transcript March 13, 2023 Operator: Good morning, and welcome to the Myomo, Inc. Fourth Quarter and Full Year 2022 Earnings Conference Call. All participants will be in listen-only mode. After today’s presentation, there will be an opportunity to ask questions. Please note that this event is being recorded. […]
Business WireMyomo Reports Fourth Quarter and Full Year 2022 Financial Results
BOSTON, March 13, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and full year ended December, 31, 2022.
Business WireMyomo to Report Fourth Quarter Financial Results on March 13, 2023
BOSTON, March 07, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and year ended December 31, 2022 on March 13, 2023 before the opening of the market.
Business WireMyomo To Participate in the 35th Annual Roth Conference
BOSTON, March 06, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that management will presenting at the 35th Annual Roth Conference, March 13-14, 2023 at The Ritz-Carlton, Dana Point, Calif. David Henry, Myomo’s chief financial officer will participate in a "Fireside Chat" on Monday, March 13th at 1:30 p.m. PT and will be
Business WireMyoPro Approved in Australia by National Disability Insurance Scheme
BOSTON, February 06, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced that for the first time, the National Disability Insurance Scheme (NDIS) in Australia approved a MyoPro for a patient with a paralyzed arm. The NDIS aids over 500,000 Australians with disabilities through reimbursement for necessary services and support.
InvestorPlace7 Top Short-Squeeze Candidates to Watch in February
While everyone knows that in order to have a market, there must be bulls and bears, that’s not going to stop people from attempting to garner intense profits from top short-squeeze candidates. To quickly summarize, shorting stocks involves borrowing shares to initiate the “negative” position. At some point, though, those borrowed shares must be returned. For the bears, they can be returned either at a profit or a loss. Now, in order to panic the bears into buying back their borrowed shares befor
Business WireMyomo Appoints Yitzchak Jacobovitz to its Board of Directors
BOSTON, January 30, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors.
Business WireMyomo Announces Closing of $6.5 Million Upsized Public Offering
BOSTON, January 17, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5
Business WireMyomo Announces Pricing of $6.5 Million Upsized Public Offering
BOSTON, January 12, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the pricing of its "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before dedu
Business WireMyomo Announces Initiative to Reduce Cash Burn
BOSTON, January 10, 2023--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced a reduction in force for the purpose of improving operating efficiency in its direct billing channel and reduce its cash burn. The action today involved the elimination of approximately 12% of its workforce, impacting employees in its call center and
Business WireMyomo Provides Update on Progress to Obtain Medicare Part B Reimbursement for MyoPro
BOSTON, December 07, 2022--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported progress and next steps in the process to obtain Medicare Part B reimbursement for the MyoPro® as a brace from the Centers for Medicare & Medicaid Services (CMS).
Business WireRuling by German Social Court Supports MyoPro Reimbursement by Nation’s Statutory Health Insurance System
BOSTON, December 05, 2022--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that in an appeal before the Berlin-Brandenburg Regional Social Court (L 9 KR 210/21), the court confirmed that the MyoPro powered whole-arm orthosis is an orthopedic aid that serves to directly compensate for disabilities. As a result of this ruling
Insider Monkey10 Best Robotic Stocks Under $10
In this article, we will be taking a look at the 10 best robotic stocks under $10. To skip our discussion on the robotics industry, you can go directly to the 5 Best Robotic Stocks Under $10. According to Statista, the size of the industrial robotics segment is expected to compound annually at an average […]
ZacksMyomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 14.89% and 4.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireMyomo Reports Third Quarter 2022 Financial Results Featuring Strong Authorizations and Orders and Record Backlog
BOSTON, November 10, 2022--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2022.
ZacksNuVasive (NUVA) Surpasses Q3 Earnings Estimates
NuVasive (NUVA) delivered earnings and revenue surprises of 1.89% and 0.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireMyomo to Report Third Quarter Financial Results on November 10, 2022
BOSTON, November 03, 2022--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2022 on November 10, 2022, after the market close.